Cardiac safety of chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults
Authors' conclusion
Six months of myostatin-activin pathway inhibition with bimagrumab had no effect on cardiac structure or function in healthy older adults compared to placebo.
Study context
- Population
- Healthy community-living men and women aged 60 to 86 years
- Participants
- 68 men
- Comparison
- IV bimagrumab 10 mg/kg vs placebo
- Primary endpoint
- Change in left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF) by cardiac MRI; changes in total lean body mass and total body fat mass by DXA
- Follow-up
- Up to 6 months
Methodological detailsdouble-blind, placebo-controlled, single commercial study site, 6 months of treatment and up to 6 months of follow-up
- Double-blind
- Placebo-controlled
- Single commercial study site
- 6 months of treatment and up to 6 months of follow-up
Primary result
As reported in the abstract
Changes in LVMI and LVEF (cardiac MRI); changes in total lean body mass and fat mass (DXA)
Mean change in total lean body mass
5.5 %
P < 0.001
SD 3.6
Mean change in total body fat mass
−14 %
P < 0.001
SD 8.9
- No clinically relevant change in left ventricular mass index (LVMI) between treatments
- least squares mean 1.6 g/m² (90% CI −0.2, 3.4; P = .148)
- No clinically relevant change in left ventricular ejection fraction (LVEF) between treatments
- 2.0% (90% CI −0.4, 4.4; P = .176)
Original publication
Cardiac safety of chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults. J Clin Endocrinol Metab. Published 25 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →